Zinc oxide nanorod based immunosensing platform for the determination of human leukemic cells

• Published in: Talanta (Oxford) 2019-08, Vol.200, p.378-386
• Main Authors: Tamashevski, Alexander, Harmaza, Yuliya, Viter, Roman, Jevdokimovs, Daniels, Poplausks, Raimond, Slobozhanina, Ekaterina, Mikoliunaite, Lina, Erts, Donats, Ramanaviciene, Almira, Ramanavicius, Arunas
• Format: Article
• Language: English
• Subjects: B-Lymphocytes - pathology; Biomarkers - blood; Cell Separation; Cells, Cultured; Flow Cytometry; Human lymphocytes; Humans; Immunoassay - methods; Leukemia - pathology; Monoclonal antibody; Nanotubes - chemistry; Photoluminescence; Zinc Oxide - chemical synthesis; Zinc Oxide - chemistry; ZnO-nanorods; В-lymphoblast cells
• ISSN: 0039-9140; 1873-3573
• DOI: 10.1016/j.talanta.2019.03.064

Zinc oxide (ZnO) based nanostructures owing unique physical properties – high photoluminescence, biocompatibility and other characteristics, therefore, they attract attention as building blocks suitable for biosensor development. In this research as a target we have used human leukemic cell line IM9 (IM9). IM9 was derived from the patient with a multiple myeloma and expressed cluster of differentiation proteins СD19 on the surface of 85–95% here investigated cancer cells. As a control sample healthy human's peripheral blood mononuclear cells (PBMC) were used and the expression of CD19 protein was found only in 5–9% of these cells. Two types of antibodies labeled by fluorescein isothiocyanate (FITC) were used for the labeling of human leukemic cells: FITC-conjugated mouse antibodies against Human CD19 protein (anti-CD19-FITC*) and FITC-conjugated mouse antibodies against Human IgG1 protein (anti-IgG1-FITC*). In order to demonstrate the applicability of zinc oxide nanorods (ZnO-NRs) based platforms three types of ZnO-NRs-based structures were investigated: (i) ZnO-NRs modified by anti-CD19-FITC*; (ii) ZnO-NRs modified by IM9 cells, which were pre-incubated with anti-CD19-FITC*; (iii) ZnO-NRs modified by PBMC cells, which were pre-incubated with anti-CD19-FITC*. It was demonstrated that IM9 cells after specific interaction with anti-CD19-FITC* bind to ZnO-NRs (ZnO-NRs/IM9 +anti-CD19-FITC*) and photoluminescence based signal significantly increase in comparison with that observed in control samples, which contained PBMC cells incubated with anti-CD19-FITC* (ZnO-NRs/PBMC+anti-CD19-FITC*). The photoluminescence results are in good correlation with the data obtained by flow cytometry. This study illustrate that ZnO-NRs exhibit a photoluminescence signal suitable for the determination of anti-CD19-FITC* labeled IM9 cell line at concentrations – from 10 till 500 cells adsorbed per 1 mm2 of ZnO-NRs platform. [Display omitted] •Photoluminescence based immunosensing platform for the detection of human leukemic cells is reported.•The platform was based on monoclonal antibody modified zinc oxide nanorod (ZnO-NR).•Cancer (B-lymphoblastoid) cells were incubated with FITC-labeled antibodies (anti-CD19-FITC*).•B-lymphoblastoid cells conjugated with anti-CD19-FITC* were fixed on ZnO-NRs surface.•ZnO-NRs photoluminescence intensity correlated with the concentration of B-lymphoblastoid cells.